Gamma Secretase (EC 3.4.23.) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Gamma Secretase (EC 3.4.23.) Drugs in Development Report Overview
Gamma secretase is a multi-subunit protease complex that is an integral membrane protein. The Gamma secretase (EC 3.4.23.) drugs in development research report provides comprehensive information on the therapeutics under development for gamma secretase. The report also analyzes the stage of development, mechanism of action (MoA), route of administration (RoA), molecule type, therapy area, and indication.
The pipeline report covers the descriptive pharmacological action and product description of gamma secretase. It includes the complete research and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in gamma secretase therapeutic development and features dormant and discontinued products.
Buy the Full Report to Know More about the Gamma Secretase Pipeline Products
| Key Therapy Areas | · Central Nervous System
· Oncology · Ear Nose Throat Disorders · Non-Malignant Disorders · Cardiovascular |
| Key Indications | · Alzheimer’s Disease
· Refractory Multiple Myeloma · Relapsed Multiple Myeloma · Adenoid Cystic Carcinoma (ACC) · Benign Tumor |
| Key Mechanisms of Action | · Gamma Secretase Inhibitor
· Gamma Secretase Modulator · Presenilin 1 Inhibitor · Presenilin 1 Activator |
| Key Routes of Administration | · Oral
· Intravenously · Intratympanically |
| Key Molecule Type | · Small Molecule
· Gene Therapy · Peptide |
| Leading Companies | · Adipo Therapeutics LLC
· AlzeCure Pharma AB · Astellas Pharma Inc · Audion Therapeutics BV · Ayala Pharmaceuticals Inc |
| Enquiry & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Gamma Secretase Pipeline Products Segmentation by Therapy Areas
A few of the key therapy areas associated with gamma secretase drugs in development are the central nervous system, oncology, ear-nose throat disorders, non-malignant disorders, and cardiovascular, among others. The central nervous system had the highest share among gamma secretase drugs in development in 2021.
Gamma Secretase Pipeline Products Analysis by Therapy Areas, 2021 (%)
Buy the Full Report for More Therapy Area Insights into the Gamma Secretase Pipeline Products
Gamma Secretase Pipeline Products Segmentation by Indications
A few of the key indications for gamma secretase drug application include Alzheimer’s disease, refractory multiple myeloma, relapsed multiple myeloma, adenoid cystic carcinoma (ACC), and benign tumor, among others. Gamma secretase drugs had the highest number of products in development for Alzheimer’s disease in 2021.
Gamma Secretase Pipeline Products Analysis by Indications, 2021 (%)
Buy the Full Report for More Indication Insights into Gamma Secretase Pipeline Products
Gamma Secretase Pipeline Products Segmentation by Mechanisms of Action
The mechanisms of action in gamma secretase drugs in development are Gamma Secretase Inhibitor, Gamma Secretase Modulator, Presenilin 1 Inhibitor, and Presenilin 1 Activator. Gamma Secretase Inhibitor accounted for the highest share of gamma secretase drugs in development in 2021.
Gamma Secretase Pipeline Products Analysis by Mechanisms of Action, 2021 (%)
Buy the Full Report for More MoA Insights into Gamma Secretase Pipeline Products
Gamma Secretase Pipeline Products Segmentation by Routes of Administration
Oral, intravenous, and intratympanic methods can administer the gamma secretase drugs. Oral RoA was the most preferred way for gamma secretase drug administration in 2021.
Gamma Secretase Pipeline Products Analysis by Routes of Administration, 2021 (%)
Buy the Full Report for More RoA Insights into Gamma Secretase Pipeline Products
Gamma Secretase Pipeline Products Segmentation by Molecule Types
The key molecule types associated with gamma secretase drugs in development are small molecule, gene therapy, and peptide. Small molecules accounted for the highest molecule type share of gamma secretase drugs in development in 2021.
Gamma Secretase Pipeline Products Analysis by Molecule Types, 2021 (%)
Buy the Full Report for More Molecule Type Insights into Gamma Secretase Pipeline Products
Gamma Secretase Pipeline Products - Competitive Landscape
Ayala Pharmaceuticals Inc. had the highest number of products in the Gamma Secretase pipeline in 2021
A few of the leading companies associated with gamma secretase pipeline products are:
- Adipo Therapeutics LLC
- AlzeCure Pharma AB
- Astellas Pharma Inc
- Audion Therapeutics BV
- Ayala Pharmaceuticals Inc
Ayala Pharmaceuticals Inc.: Ayala Pharmaceuticals is headquartered in Wilmington, Delaware, the US. It is a clinical-stage biopharmaceutical company developing novel drugs for genomically-defined cancers. The company focuses on inhibiting the Notch activating pathway with best-in-class gamma secretase inhibitors (GSIs).
Gamma Secretase Pipeline Products Analysis by Companies, 2021 (%)
Buy the Full Report for More Company Insights into Gamma Secretase Pipeline Products
Gamma Secretase Pipeline Products - Featured News
21st April 2021: Ayala Pharmaceuticals Inc. focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company announced the dosing of the first patient in the ongoing Phase 1 clinical trial evaluating its potent investigational gamma secretase inhibitor (GSI), AL102, in combination with Novartis’ investigational anti-B-cell maturation antigen (BCMA) agent, WVT078, for the treatment of patients with relapsed and/or refractory multiple myeloma (MM).
Buy the Full Report to Know More Featured News about Gamma Secretase Pipeline Products
Segments Covered in the Report
Gamma Secretase Pipeline Products Therapy Area Outlook (2021)
- Central Nervous System
- Oncology
- Ear Nose Throat Disorders
- Non-Malignant Disorders
- Cardiovascular
Gamma Secretase Pipeline Products Indication Outlook (2021)
- Alzheimer’s Disease
- Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Adenoid Cystic Carcinoma (ACC)
- Benign Tumor
Gamma Secretase Pipeline Products MoA Outlook (2021)
- Gamma Secretase Inhibitor
- Gamma Secretase Modulator
- Presenilin 1 Inhibitor
- Presenilin 1 Activator
Gamma Secretase Pipeline Products RoA Outlook (2021)
- Oral
- Intravenously
- Intratympanically
Gamma Secretase Pipeline Products Molecule Type Outlook (2021)
- Gene Therapy
- Peptide
Scope
The report provides:
- A snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.).
- Review of targeted therapeutics for Gamma Secretase (EC 3.4.23.) by companies and universities/research institutes. The review is based on information derived from company and industry-specific sources.
- Information about pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlisted all their major and minor projects.
- Assessment of Gamma Secretase (EC 3.4.23.) targeted therapeutics based on their mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics.
Reasons to Buy
- Gain strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.).
- Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding the Gamma Secretase (EC 3.4.23.) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
AlzeCure Pharma AB
Astellas Pharma Inc
Audion Therapeutics BV
Ayala Pharmaceuticals Inc
Eli Lilly and Co
Everfront Biotech Inc
F. Hoffmann-La Roche Ltd
Laminar Pharmaceuticals SA
Merck & Co Inc
NeuroGenetic Pharmaceuticals Inc
Pharchoice Therapeutics Inc
Pipeline Therapeutics Inc
SpringWorks Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which was the leading therapy area in gamma secretase drugs in development in 2021?
The central nervous system had the highest share among gamma secretase drugs in development in 2021.
-
Which was the leading indication for gamma secretase drugs in development in 2021?
Gamma secretase drugs had the highest number of products in development for Alzheimer’s disease in 2021.
-
Which was the leading mechanism of action for gamma secretase drugs in development in 2021?
Gamma Secretase Inhibitor accounted for the highest share of gamma secretase drugs in development in 2021.
-
Which was the leading route of administration for gamma secretase drugs in development in 2021?
Oral RoA was the most preferred way for gamma secretase drug administration in 2021.
-
Which are the leading companies associated with gamma secretase drugs in development?
A few of the leading companies associated with the gamma secretase pipeline products are Adipo Therapeutics LLC, AlzeCure Pharma AB, Astellas Pharma Inc, Audion Therapeutics BV, and Ayala Pharmaceuticals Inc, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Gamma Secretase (EC 3.4.23.) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports